Back to search
FDAFDA · Food and drugs·Recall number D-1613-2014

Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.

Published October 8, 2014 · Recall initiated: May 5, 2014

Summary

FDA records drug Class I recall D-1613-2014, published October 8, 2014 and initiated May 5, 2014. Recalling firm: Eugene Oregon, Inc.; Status: Terminated; Reported quantity: 136 boxes; Lot: All lots. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Eugene Oregon, Inc.
Distributor
To retailers in MD, TX, FL, PA, IL, NJ, IN, LA, WA, ME, SC
Lot
All lots
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd. recalled?

Yes. FDA published recall D-1613-2014 on October 8, 2014. Reported hazard: Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

What should I do if I have this product?

Voluntary: Firm initiated · Letter